Comparative Pharmacology
Head-to-head clinical analysis: DECASPRAY versus NASONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECASPRAY versus NASONEX.
DECASPRAY vs NASONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.
Corticosteroid with anti-inflammatory activity; binds to glucocorticoid receptors, inhibiting inflammatory mediators like prostaglandins and leukotrienes.
2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.
Mometasone furoate 200 mcg per day as 2 sprays (50 mcg/spray) in each nostril once daily. May reduce to 100 mcg per day (1 spray per nostril once daily) if symptoms controlled. Maximum 200 mcg per day.
None Documented
None Documented
The terminal elimination half-life is approximately 3-4 hours in adults. This short half-life is consistent with its classification as a long-acting glucocorticoid due to high potency and prolonged tissue effects, not extended plasma presence.
The terminal elimination half-life of mometasone furoate following intranasal administration is approximately 5.8 hours (range 2.7–11.5 hours) in adults, reflecting rapid clearance from systemic circulation.
Decaspray (dexamethasone) is primarily metabolized in the liver, with less than 10% excreted unchanged in urine. Minor biliary excretion occurs, but fecal elimination is negligible. Overall, renal excretion accounts for >90% as metabolites, with <10% as parent drug.
Mometasone furoate is extensively metabolized in the liver, primarily via CYP3A4, and metabolites are excreted mostly in feces (approximately 74%) and to a lesser extent in urine (approximately 8%).
Category C
Category C
Intranasal Corticosteroid
Intranasal Corticosteroid